NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10673	Companies
227589	Keywords
155974	Articles
120537	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 02/12/2025 at 22:15, 1 year 4 months ago

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Communiqué mensuel de Nanobiotix sur les droits de vote et actions. Informations financières conformes à la règlementation des marchés financiers. Nanobiotix, société de biotechnologie, cotée à Euronext Paris et Nasdaq, développe des traitements innovants

Euronext Paris Biotechnologie Nasdaq NANOBIOTIX Traitements Innovants
PRESS RELEASE

published on 02/12/2025 at 22:15, 1 year 4 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital details. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 12/17/2024 at 22:20, 1 year 6 months ago

NANOBIOTIX Prépare son Événement Virtuel Révolutionnaire

Cancer NANOBIOTIX Technologie Nanothérapeutique Curadigm Médicaments Intraveineux
BRIEF

published on 12/17/2024 at 22:20, 1 year 6 months ago

NANOBIOTIX Prepares its Revolutionary Virtual Event

Cancer NANOBIOTIX Curadigm Nanotherapeutic Technology Intravenous Medications
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX présentera sa vision pour révolutionner la conception et le développement de médicaments à travers sa prochaine plateforme nanothérapeutique le 19 décembre 2024
Nanobiotix présente sa plateforme nanothérapeutique lors d'un événement virtuel le 19/12 à 15h00 CET / 9h00 ET pour améliorer les traitements pour les patients atteints de cancer

Innovation Cancer Événement Virtuel NANOBIOTIX Nanothérapeutique
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development

Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF

published on 12/09/2024 at 22:20, 1 year 6 months ago

Nanobiotix conclut avec succès une étude de phase 1 sur le cancer du pancréas

FDA Étude De Phase 1 Cancer Du Pancréas Chimiothérapie Radiothérapie
BRIEF

published on 12/09/2024 at 22:20, 1 year 6 months ago

Nanobiotix successfully completes phase 1 study in pancreatic cancer

FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX annonce l’achèvement de l’étude de phase 1 avec NBTXR3 (JNJ-1900) dans le cancer du pancréas
Nanobiotix annonce l'achèvement de l'étude de Phase 1 avec NBTXR3 dans le cancer du pancréas, avec des résultats encourageants. Un essai randomisé est prévu. Plus d'informations sur www.nanobiotix.com

Étude De Phase 1 Cancer Du Pancréas NANOBIOTIX NBTXR3 Essai Randomisé
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025

FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study

Accesswire

Published on 07/01/2026 at 17:00, 2 hours 21 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 07/01/2026 at 14:30, 4 hours 51 minutes ago

AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 5 hours 51 minutes ago

Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 6 hours 21 minutes ago

Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 16 hours 6 minutes ago

GLG Life Tech Corporation Announces 2026 AGM Voting Results

View all ACCESSWIRE

EQS Group

Published on 07/01/2026 at 19:00, 21 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 07/01/2026 at 19:00, 21 minutes ago

OLB strengthens its leadership team to drive the next phase of growth
Published on 07/01/2026 at 18:55, 26 minutes ago

OLB Ensures Leadership Continuity Following Management Board Changes / Christophe Jéhan assumes responsibilities for Marc Ampaw’s business areas on interim basis
Published on 07/01/2026 at 18:29, 52 minutes ago

Aperam Update on Q2 2026 market & financial trends
Published on 07/01/2026 at 18:29, 52 minutes ago

Aperam Update on Q2 2026 market & financial trends

Les Echos

Published on 07/01/2026 at 18:40, 40 minutes ago

LNA SANTE : Acquisition de 5 EHPAD
Published on 07/01/2026 at 18:26, 54 minutes ago

Modula renews its confidence in AMA with a four-year agreement integrating XpertEye’s new AI-powered features
Published on 07/01/2026 at 18:26, 54 minutes ago

Modula renouvelle sa confiance à AMA avec un contrat de quatre ans intégrant les nouvelles fonctionnalités IA d’XpertEye
Published on 07/01/2026 at 18:01, 1 hour 20 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 07/01/2026 at 17:54, 1 hour 26 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Juin 2026

View all LES ECHOS COMFI WIRE